HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil.

AbstractOBJECTIVES:
Physical exercise may benefit people with Alzheimer's disease (AD) and mild cognitive impairment (MCI). However, randomised controlled trials (RCTs) of exercise have shown conflicting findings and it is unclear if positive outcomes are comparable to a commonly used cholinesterase inhibitor, donepezil.
METHODS:
Embase, Medline, PsycINFO, PsycARTICLES, SCOPUS were searched for RCTs of physical activity compared to a control condition, and donepezil compared to placebo in people with AD and MCI. Effect sizes were calculated from pre- and post-MMSE and ADAS-Cog scores and pooled using a random effects meta-analysis.
RESULTS:
Ninteen RCTs were included in the exercise meta-analysis (AD, N = 524; MCI, N = 1269). Physical exercise improved MMSE scores in AD (Hedges' g = 0.46) and MCI groups (g = 0.63). For the MCI group, exercise appeared to have a stronger effect for those with lower MMSE scores at baseline (p = 0.022). 18 RCTs were included in the donepezil meta-analysis (AD, N = 2984, MCI, N = 1559). In people with AD, donepezil improved cognition (MMSE g = 0.23; ADAS-Cog, g = -0.17) but there was no evidence of improved cognition in MCI.
CONCLUSIONS:
Physical exercise improved cognition in both AD and MCI groups. Where comparisons were possible, the effect size for physical exercise was generally comparable to donepezil. These results strengthen the evidence base for exercise as an effective intervention in AD and MCI, and future clinical trials should examine exercise type, intensity and frequency, in addition to cholinesterase inhibitors to determine the most effective interventions for AD and MCI.
AuthorsSara Pisani, Christoph Mueller, Jonathan Huntley, Dag Aarsland, Matthew J Kempton
JournalInternational journal of geriatric psychiatry (Int J Geriatr Psychiatry) Vol. 36 Issue 10 Pg. 1471-1487 (10 2021) ISSN: 1099-1166 [Electronic] England
PMID34490652 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
Copyright© 2021 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.
Chemical References
  • Cholinesterase Inhibitors
  • Donepezil
Topics
  • Alzheimer Disease (drug therapy)
  • Cholinesterase Inhibitors (therapeutic use)
  • Cognitive Dysfunction (drug therapy)
  • Donepezil (therapeutic use)
  • Exercise
  • Humans
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: